whatshot

URGN   $29.5  5.36% Market Closed After Close 29.5 0.0

UroGen Pharma Ltd.
show_chart Advanced Chart of URGN
Last Events:

2023-08-09 Signal in RSI changed from bullish recovery to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-08-09 Trend Power changed from medium strength to slow.

2023-08-06 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-06 Trend Power changed from slow to medium strength.

2023-08-05 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bullish weakening to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-08-02 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 8
Target Price Mean 36.88
Mean unverified/preliminary 36.88 / 36.88
Target Price Low / High 18.00 / 45.00
Median / STD DEV 40.00 / 8.72
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell None
macd None None None
stoch None None None
ma20 Sell Sell Sell
ma50 None None None
ma100 Sell Sell Sell
Candlestick PatternJune 11, 2026 Three Stars -
ISIN IL0011407140
ceo Ms. Elizabeth A. Barrett
Website https://www.urogen.com
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.